TY - JOUR
T1 - The impact of personalized medicine on survival
T2 - Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers
AU - Rossi, Antonio
AU - Torri, Valter
AU - Garassino, Marina Chiara
AU - Porcu, Luca
AU - Galetta, Domenico
PY - 2014/5
Y1 - 2014/5
N2 - Breast, colorectal and lung cancers represent the three most incident forms of cancer worldwide. Among these three "big killers", lung cancer is considered the one with the worst prognosis due to its high mortality even in early stages. Due to their more favorable prognosis, breast and colorectal cancers might appear to have benefited from major advances. Most oncologists who are faced with metastatic non-small cell lung cancer (NSCLC) find the reported results very frustrating when compared with those for metastatic breast (MBC) and colorectal cancers (MCRC). The aim of this analysis was to quantify and compare the relative magnitude of overall survival (OS) improvements in the first-line approaches in metastatic NSCLC, MBC and MCRC through the analysis of the main landmark meta-analyses and randomized clinical trials (RCTs) of commercially available drugs. Five items were considered and analyzed for each cancer. Moreover we evaluated the real clinical impact of the results reported by each item on the entire population; for each "big killer" an overall hazard ratio (HR) was estimated: 0.88 (95%+ CI: 0.72-1.07) for MBC, 0.94 (95%+ CI: 0.82-1.07) for MCRC, and about 0.80 (95%+ CI: 0.73-0.90) for advanced NSCLC. We showed that, in the last decades, these three tumors had important and constant OS improvements reached step by step. The relative magnitude of OS improvement seems higher in metastatic NSCLC than MBC and MCRC.
AB - Breast, colorectal and lung cancers represent the three most incident forms of cancer worldwide. Among these three "big killers", lung cancer is considered the one with the worst prognosis due to its high mortality even in early stages. Due to their more favorable prognosis, breast and colorectal cancers might appear to have benefited from major advances. Most oncologists who are faced with metastatic non-small cell lung cancer (NSCLC) find the reported results very frustrating when compared with those for metastatic breast (MBC) and colorectal cancers (MCRC). The aim of this analysis was to quantify and compare the relative magnitude of overall survival (OS) improvements in the first-line approaches in metastatic NSCLC, MBC and MCRC through the analysis of the main landmark meta-analyses and randomized clinical trials (RCTs) of commercially available drugs. Five items were considered and analyzed for each cancer. Moreover we evaluated the real clinical impact of the results reported by each item on the entire population; for each "big killer" an overall hazard ratio (HR) was estimated: 0.88 (95%+ CI: 0.72-1.07) for MBC, 0.94 (95%+ CI: 0.82-1.07) for MCRC, and about 0.80 (95%+ CI: 0.73-0.90) for advanced NSCLC. We showed that, in the last decades, these three tumors had important and constant OS improvements reached step by step. The relative magnitude of OS improvement seems higher in metastatic NSCLC than MBC and MCRC.
KW - Biologic agents
KW - Breast cancer
KW - Chemotherapy
KW - Colorectal cancer
KW - Maintenance therapy
KW - Meta-analysis
KW - Metastatic disease
KW - Non-small cell lung cancer
KW - Randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=84896697788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896697788&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2013.09.012
DO - 10.1016/j.ctrv.2013.09.012
M3 - Article
C2 - 24112813
AN - SCOPUS:84896697788
VL - 40
SP - 485
EP - 494
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
IS - 4
ER -